Cullinan’s Zipalertinib Gains First-Line Momentum Against J&J and AstraZeneca in EGFR Exon 20 NSCLC

Cullinan/Taiho’s oral EGFR exon 20 insertion inhibitor zipalertinib showed a strong first-line signal in the Phase 3 REZILIENT3 trial:
median progression-free survival was 14.5 months with zipalertinib plus chemotherapy versus 8.5 months with chemotherapy alone (HR 0.50; P=0.00015), with response rates of 65.0% versus 40.3%.

The result gives zipalertinib a credible chance to challenge Johnson & Johnson’s Rybrevant in frontline treatment, particularly because zipalertinib is oral and designed to spare wild-type EGFR, potentially improving tolerability and convenience. However, the comparison is indirect:
REZILIENT3’s interim PFS result cannot be directly ranked against J&J’s PAPILLON data.

J&J retains the strongest established position. Rybrevant plus chemotherapy is approved in the first line, and final PAPILLON results reported median overall survival of 34.3 months versus 27.9 months with chemotherapy alone, although the OS difference was not statistically significant and substantial crossover may have diluted the comparison.

AstraZeneca is rapidly strengthening its position through licensed sunvozertinib (Zegfrovy), an oral EGFR inhibitor already approved after platinum therapy in the U.S. and China. Its positive first-line WU-KONG28 results support a pending supplemental application, but it does not yet have the same first-line regulatory or commercial foothold as Rybrevant.

Bottom line:
zipalertinib may outpace AstraZeneca’s sunvozertinib in first-line momentum if its PFS benefit translates into durable overall-survival and safety advantages. Overtaking J&J will be harder because Rybrevant has approval, guideline presence, mature survival data, and a growing subcutaneous formulation. Key swing factors are final REZILIENT3 OS, toxicity, CNS activity, regulatory timing, and head-to-head or comparable real-world evidence.